

Datasheet: PIP013

BATCH NUMBER 158181

Description:	NATIVE MEASLES VIRUS
Name:	MEASLES VIRUS
Format:	Inactivated Pathogen
Product Type:	Antigen
Quantity:	1 ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Viral
Product Form	Inactivated Measles virus - liquid
Preparation	Measles virus, Edmonston strain, cultured in Vero cells. Optimally infected cells are disrupted in culture fluids. The suspension is clarified and concentrated by crossflow ultrafiltration. The antigen preparation is inactivated using gamma radiation, which primarily damages viral genetic material.
Buffer Solution	Minimum Essential Medium
Preservative Stabilisers	None present
Approx. Protein Concentrations	Total protein concentration 2.3 mg/ml
Product Information	Native Measles Virus preparation contains a high concentration of virus and viral components. The preparation also contains some cellular material suspended in tissue culture medium.

The Measles virus is a highly contagious single-stranded RNA virus that is mostly spread via the respiratory system. It may be passed via aerosol droplets from coughs or through contact with infected bodily fluids. It causes measles, a disease characterised by fever, cough, runny nose, red eyes and a rash. Most patients with uncomplicated measles will recover without antiviral treatment, however, some patients may develop diarrhoea, corneal ulceration, pneumonia or encephalitis. Complications are more likely in adults. In developed countries, most children are immunised against measles by the age of 18 months, as part of the three-part MMR (measles, mumps and rubella) vaccine.

Activity	Antigenic activity is 104% of internal reference standard.
Instructions For Use	PIP013 should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats or may be further purified to meet the requirements of a particular assay format.
References	1. Bhoj, V.G. <i>et al.</i> (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 128 (3): 360-70.
Storage	Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.
Guarantee	12 months from date of despatch
Health And Safety Information	Material Safety Datasheet documentation #10286 available at: https://www.bio-rad-antibodies.com/SDS/PIP013 10286 This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately.
Regulatory	For research purposes only

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)
'M378979:210319'

Printed on 07 Nov 2024